Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications
Abstract
:1. Introduction
2. Hypoxia and the Skin
3. Oxygen Sensing and Hypoxia Signaling Pathways
4. Genetic and Molecular Basis of Hypoxia Signaling in Skin Cancer
4.1. Melanomas
4.1.1. BRAF
4.1.2. RAS and NF1
4.1.3. CDNK2A
4.1.4. MITF
4.2. Basal Cell Carcinoma
4.3. Cutaneous Squamous Cell Carcinoma
4.4. Rare Types of Skin Cancer
5. Hypoxia and Reconstruction after Skin Cancer Resection
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bedogni, B.; Powell, M.B. Hypoxia, melanocytes and melanoma—Survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res. 2009, 22, 166–174. [Google Scholar] [CrossRef] [PubMed]
- Wysocki, A.B. Skin anatomy, physiology, and pathophysiology. Nurs. Clin. N. Am. 1999, 34, 777–797. [Google Scholar] [CrossRef]
- Evans, S.M.; Schrlau, A.E.; Chalian, A.A.; Zhang, P.; Koch, C.J. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J. Investig. Dermatol. 2006, 126, 2596–2606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, W.; Winlove, C.P.; Michel, C.C. Oxygen partial pressure in outer layers of skin of human finger nail folds. J. Physiol. 2003, 549, 855–863. [Google Scholar] [CrossRef] [PubMed]
- Koch, C.J. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Method Enzymol. 2002, 352, 3–31. [Google Scholar]
- Simoes, M.C.F.; Sousa, J.J.S.; Pais, A. Skin cancer and new treatment perspectives: A review. Cancer Lett. 2015, 357, 8–42. [Google Scholar] [CrossRef] [PubMed]
- Saladi, R.N.; Persaud, A.N. The causes of skin cancer: A comprehensive review. Drugs Today 2005, 41, 37–53. [Google Scholar] [CrossRef]
- Lens, M. Current clinical overview of cutaneous melanoma. Br. J. Nurs. 2008, 17, 300–305. [Google Scholar] [CrossRef] [PubMed]
- Marks, R. An overview of skin cancers. Incidence and causation. Cancer 1995, 75, 607–612. [Google Scholar] [CrossRef]
- Yang, D.D.; Salciccioli, J.D.; Marshall, D.C.; Sheri, A.; Shalhoub, J. Trends in malignant melanoma mortality in 31 countries from 1985 to 2015. Br. J. Dermatol. 2020, 183, 1056–1064. [Google Scholar] [CrossRef]
- Madan, V.; Lear, J.T.; Szeimies, R.M. Non-melanoma skin cancer. Lancet 2010, 375, 673–685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Semenza, G.L. Hypoxia and cancer. Cancer Metastasis Rev. 2007, 26, 223–224. [Google Scholar] [CrossRef] [PubMed]
- Chouaib, S.; Messai, Y.; Couve, S.; Escudier, B.; Hasmim, M.; Noman, M.Z. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 2012, 3, 21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muz, B.; de la Puente, P.; Azab, F.; Azab, A.K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 2015, 3, 83–92. [Google Scholar] [CrossRef] [Green Version]
- Wang, G.L.; Semenza, G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995, 270, 1230–1237. [Google Scholar] [CrossRef] [Green Version]
- Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510–5514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanimoto, K.; Makino, Y.; Pereira, T.; Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19, 4298–4309. [Google Scholar] [CrossRef] [Green Version]
- Srinivas, V.; Zhang, L.P.; Zhu, X.H.; Caro, J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem. Biophys. Res. Commun. 1999, 260, 557–561. [Google Scholar] [CrossRef]
- Ohh, M.; Park, C.W.; Ivan, M.; Hoffman, M.A.; Kim, T.Y.; Huang, L.E.; Pavletich, N.; Chau, V.; Kaelin, W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2000, 2, 423–427. [Google Scholar] [CrossRef]
- Maxwell, P.H.; Wiesener, M.S.; Chang, G.W.; Clifford, S.C.; Vaux, E.C.; Cockman, M.E.; Wykoff, C.C.; Pugh, C.W.; Maher, E.R.; Ratcliffe, P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271–275. [Google Scholar] [CrossRef]
- Jaakkola, P.; Mole, D.R.; Tian, Y.M.; Wilson, M.I.; Gielbert, J.; Gaskell, S.J.; von Kriegsheim, A.; Hebestreit, H.F.; Mukherji, M.; Schofield, C.J.; et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468–472. [Google Scholar] [CrossRef] [PubMed]
- Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G., Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001, 292, 464–468. [Google Scholar] [CrossRef] [PubMed]
- Ivan, M.; Haberberger, T.; Gervasi, D.C.; Michelson, K.S.; Gunzler, V.; Kondo, K.; Yang, H.; Sorokina, I.; Conaway, R.C.; Conaway, J.W.; et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA 2002, 99, 13459–13464. [Google Scholar] [CrossRef] [Green Version]
- Weidemann, A.; Johnson, R.S. Biology of HIF-1alpha. Cell Death Differ. 2008, 15, 621–627. [Google Scholar] [CrossRef] [Green Version]
- Mahon, P.C.; Hirota, K.; Semenza, G.L. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15, 2675–2686. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lando, D.; Peet, D.J.; Whelan, D.A.; Gorman, J.J.; Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002, 295, 858–861. [Google Scholar] [CrossRef]
- Hu, C.J.; Wang, L.Y.; Chodosh, L.A.; Keith, B.; Simon, M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell Biol. 2003, 23, 9361–9374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Keith, B.; Johnson, R.S.; Simon, M.C. HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12, 9–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duan, C. Hypoxia-inducible factor 3 biology: Complexities and emerging themes. Am. J. Physiol. Cell Physiol. 2016, 310, C260–C269. [Google Scholar] [CrossRef] [Green Version]
- Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732. [Google Scholar] [CrossRef]
- Pezzuto, A.; Carico, E. Role of HIF-1 in Cancer Progression: Novel Insights. A Review. Curr. Mol. Med. 2018, 18, 343–351. [Google Scholar] [CrossRef] [PubMed]
- Nys, K.; Maes, H.; Dudek, A.M.; Agostinis, P. Uncovering the role of hypoxia inducible factor-1alpha in skin carcinogenesis. Biochim. Biophys. Acta 2011, 1816, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Rezvani, H.R.; Ali, N.; Nissen, L.J.; Harfouche, G.; de Verneuil, H.; Taieb, A.; Mazurier, F. HIF-1alpha in epidermis: Oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J. Investig. Dermatol. 2011, 131, 1793–1805. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giatromanolaki, A.; Sivridis, E.; Kouskoukis, C.; Gatter, K.C.; Harris, A.L.; Koukourakis, M.I. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003, 13, 493–501. [Google Scholar] [CrossRef]
- Bedogni, B.; Powell, M.B. Skin hypoxia—A promoting environmental factor in melanomagenesis. Cell Cycle 2006, 5, 1258–1261. [Google Scholar] [CrossRef]
- D’Aguanno, S.; Mallone, F.; Marenco, M.; Del Bufalo, D.; Moramarco, A. Hypoxia-dependent drivers of melanoma progression. J. Exp. Clin. Cancer Res. 2021, 40, 159. [Google Scholar] [CrossRef]
- Chang, A.E.; Karnell, L.H.; Menck, H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma—A summary of 84,836 cases from the past decade. Cancer 1998, 83, 1664–1678. [Google Scholar] [CrossRef]
- Schadendorf, D.; Fisher, D.E.; Garbe, C.; Gershenwald, J.E.; Grob, J.J.; Halpern, A.; Herlyn, M.; Marchetti, M.A.; McArthur, G.; Ribas, A.; et al. Melanoma. Nat. Rev. Dis. Prim. 2015, 1, 15003. [Google Scholar] [CrossRef]
- Pfeifer, G.P. Mechanisms of UV-induced mutations and skin cancer. Genome Instab. Dis. 2020, 1, 99–113. [Google Scholar] [CrossRef] [Green Version]
- Akbani, R.; Akdemir, K.C.; Aksoy, B.A.; Albert, M.; Ally, A.; Amin, S.B.; Arachchi, H.; Arora, A.; Auman, J.T.; Ayala, B.; et al. Genomic Classification of Cutaneous Melanoma. Cell 2015, 161, 1681–1696. [Google Scholar] [CrossRef] [Green Version]
- Hayward, N.K.; Wilmott, J.S.; Waddell, N.; Johansson, P.A.; Field, M.A.; Nones, K.; Patch, A.M.; Kakavand, H.; Alexandrov, L.B.; Burke, H.; et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017, 545, 175–180. [Google Scholar] [CrossRef] [PubMed]
- Rabbie, R.; Ferguson, P.; Molina-Aguilar, C.; Adams, D.J.; Robles-Espinoza, C.D. Melanoma subtypes: Genomic profiles, prognostic molecular markers and therapeutic possibilities. J. Pathol. 2019, 247, 539–551. [Google Scholar] [CrossRef] [PubMed]
- Reddy, B.Y.; Miller, D.M.; Tsao, H. Somatic Driver Mutations in Melanoma. Cancer 2017, 123, 2104–2117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scatena, C.; Murtas, D.; Tomei, S. Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies. Front. Oncol 2021, 11, 635488. [Google Scholar] [CrossRef]
- Read, J.; Wadt, K.A.W.; Hayward, N.K. Melanoma genetics. J. Med. Genet. 2016, 53, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Hussussian, C.J.; Struewing, J.P.; Goldstein, A.M.; Higgins, P.A.T.; Ally, D.S.; Sheahan, M.D.; Clark, W.H.; Tucker, M.A.; Dracopoli, N.C. Germline P16 Mutations in Familial Melanoma. Nat. Genet. 1994, 8, 15–21. [Google Scholar] [CrossRef]
- Kamb, A.; Shattuckeidens, D.; Eeles, R.; Liu, Q.; Gruis, N.A.; Ding, W.; Hussey, C.; Tran, T.; Miki, Y.; Weaverfeldhaus, J.; et al. Analysis of the P16 Gene (Cdkn2) as a Candidate for the Chromosome 9p Melanoma Susceptibility Locus. Nat. Genet. 1994, 8, 22–26. [Google Scholar] [CrossRef]
- Zuo, L.; Weger, J.; Yang, Q.B.; Goldstein, A.M.; Tucker, M.A.; Walker, G.J.; Hayward, N.; Dracopoli, N.C. Germline mutations in the p16(INK4a) binding domain of CDK4 in familial melanoma. Nat. Genet. 1996, 12, 97–99. [Google Scholar] [CrossRef]
- Aoude, L.G.; Wadt, K.A.W.; Pritchard, A.L.; Hayward, N.K. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 2015, 28, 148–160. [Google Scholar] [CrossRef]
- Huang, C.; Radi, R.H.; Arbiser, J.L. Mitochondrial Metabolism in Melanoma. Cells 2021, 10, 3197. [Google Scholar] [CrossRef]
- Ashton, T.M.; McKenna, W.G.; Kunz-Schughart, L.A.; Higgins, G.S. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clin. Cancer Res. 2018, 24, 2482–2490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haq, R.; Shoag, J.; Andreu-Perez, P.; Yokoyama, S.; Edelman, H.; Rowe, G.C.; Frederick, D.T.; Hurley, A.D.; Nellore, A.; Kung, A.L.; et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013, 23, 302–315. [Google Scholar] [CrossRef] [Green Version]
- Yuan, P.; Ito, K.; Perez-Lorenzo, R.; Del Guzzo, C.; Lee, J.H.; Shen, C.H.; Bosenberg, M.W.; McMahon, M.; Cantley, L.C.; Zheng, B. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc. Natl. Acad. Sci. USA 2013, 110, 18226–18231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vazquez, F.; Lim, J.H.; Chim, H.; Bhalla, K.; Girnun, G.; Pierce, K.; Clish, C.B.; Granter, S.R.; Widlund, H.R.; Spiegelman, B.M.; et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23, 287–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Porporato, P.E.; Payen, V.L.; Perez-Escuredo, J.; De Saedeleer, C.J.; Danhier, P.; Copetti, T.; Dhup, S.; Tardy, M.; Vazeille, T.; Bouzin, C.; et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014, 8, 754–766. [Google Scholar] [CrossRef] [Green Version]
- LeBleu, V.S.; O’Connell, J.T.; Gonzalez Herrera, K.N.; Wikman, H.; Pantel, K.; Haigis, M.C.; de Carvalho, F.M.; Damascena, A.; Domingos Chinen, L.T.; Rocha, R.M.; et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 2014, 16, 992–1003. [Google Scholar] [CrossRef] [Green Version]
- Wallace, D.C. Mitochondria and cancer. Nat. Rev. Cancer 2012, 12, 685–698. [Google Scholar] [CrossRef] [Green Version]
- Xiong, W.; Qi, L.; Jiang, N.; Zhao, Q.; Chen, L.; Jiang, X.; Li, Y.; Zhou, Z.; Shen, J. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy. ACS Appl. Mater. Interfaces 2021, 13, 8026–8041. [Google Scholar] [CrossRef]
- Du, Y.N.; Li, Y.N.; Li, X.Z.; Jia, C.R.; Wang, L.; Wang, Y.Q.; Ding, Y.; Wang, S.; Sun, H.M.; Sun, W.; et al. Sequential Enzyme Activation of a “Pro-Staramine”-Based Nanomedicine to Target Tumor Mitochondria. Adv. Funct. Mater. 2020, 30, 1904697. [Google Scholar] [CrossRef]
- Zheng, C.J.; Luo, W.J.; Liu, Y.; Chen, J.S.; Deng, H.; Zhou, Z.G.; Shen, J.L. Killing three birds with one stone: Multi-stage metabolic regulation mediated by clinically usable berberine liposome to overcome photodynamic immunotherapy resistance. Chem. Eng. J. 2023, 454, 140164. [Google Scholar] [CrossRef]
- Fecher, L.A.; Arnaravadi, R.K.; Flaherty, K.T. The MAPK pathway in melanoma. Curr. Opin. Oncol. 2008, 20, 183–189. [Google Scholar] [CrossRef]
- Ascierto, P.A.; Kirkwood, J.M.; Grob, J.J.; Simeone, E.; Grimaldi, A.M.; Maio, M.; Palmieri, G.; Testori, A.; Marincola, F.M.; Mozzillo, N. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 2012, 10, 85. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumar, S.M.; Yu, H.; Edwards, R.; Chen, L.J.; Kazianis, S.; Brafford, P.; Acs, G.; Herlyn, M.; Xu, X.W. Mutant V600E BRAF increases hypoxia inducible factor-1 alpha expression in melanoma. Cancer Res. 2007, 67, 3177–3184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jo, Y.S.; Li, S.J.; Song, J.H.; Kwon, K.H.; Lee, J.C.; Rha, S.Y.; Lee, H.J.; Sul, J.Y.; Kweon, G.R.; Ro, H.K.; et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2006, 91, 3667–3670. [Google Scholar] [CrossRef]
- Bottos, A.; Martini, M.; Di Nicolantonio, F.; Comunanza, V.; Maione, F.; Minassi, A.; Appendino, G.; Bussolino, F.; Bardelli, A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc. Natl. Acad. Sci. USA 2012, 109, E353–E359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, S.J.; Zhang, G.; Guo, J.P.; Chen, X.; Lei, J.C.; Ze, K.; Dong, L.Y.; Dai, X.P.; Gao, Y.; Song, D.S.; et al. Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis. Nat. Commun. 2019, 9, 5426. [Google Scholar] [CrossRef] [Green Version]
- Flaherty, K.T.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; O’Dwyer, P.J.; Lee, R.J.; Grippo, J.F.; Nolop, K.; et al. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N. Engl. J. Med. 2010, 363, 809–819. [Google Scholar] [CrossRef] [Green Version]
- Livingstone, E.; Zimmer, L.; Piel, S.; Schadendorf, D. PLX4032: Does it keep its promise for metastatic melanoma treatment? Expert Opin. Investig. Drugs 2010, 19, 1439–1449. [Google Scholar] [CrossRef]
- Eckerich, C.; Zapf, S.; Fillbrandt, R.; Loges, S.; Westphal, M.; Lamszus, K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int. J. Cancer 2007, 121, 276–283. [Google Scholar] [CrossRef] [PubMed]
- Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3, 347–361. [Google Scholar] [CrossRef] [Green Version]
- Yu, F.; Lin, Y.H.; Zhan, T.; Guo, S.F.; Chen, L.L. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol. Int. 2015, 39, 310–317, Erratum in Cell Biol. Int. 2021, 45, 1350. [Google Scholar] [CrossRef]
- Qin, Y.; Roszik, J.; Chattopadhyay, C.; Hashimoto, Y.; Liu, C.W.; Cooper, Z.A.; Wargo, J.A.; Hwu, P.; Ekmekcioglu, S.; Grimm, E.A. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol. Cancer Ther. 2016, 15, 2442–2454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murphy, M.; Phelps, A.; Swede, H.; Claffey, K. Hypoxia-induced response of cell cycle and apoptosis regulators in melanoma. Int. J. Dermatol. 2012, 51, 1263–1267. [Google Scholar] [CrossRef] [PubMed]
- Kiuru, M.; Busam, K.J. The NF1 gene in tumor syndromes and melanoma. Lab. Investig. 2017, 97, 146–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al Mahi, A.; Ablain, J. RAS pathway regulation in melanoma. Dis. Model. Mech. 2022, 15, dmm049229. [Google Scholar] [CrossRef]
- Yang, Y.; Wu, J.; Demir, A.; Castillo-Martin, M.; Melamed, R.D.; Zhang, G.; Fukunaga-Kanabis, M.; Perez-Lorenzo, R.; Zheng, B.; Silvers, D.N.; et al. GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene 2013, 32, 3627–3637. [Google Scholar] [CrossRef] [Green Version]
- Monsel, G.; Ortonne, N.; Bagot, M.; Bensussan, A.; Dumaz, N. c-Kit mutants require hypoxia-inducible factor 1 alpha to transform melanocytes. Oncogene 2010, 29, 227–236. [Google Scholar] [CrossRef] [Green Version]
- Green, Y.S.; Sargis, T.; Reichert, E.C.; Rudasi, E.; Fuja, D.; Jonasch, E.; Koh, M.Y. Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. Mol. Cancer Res. 2019, 17, 1220–1232. [Google Scholar] [CrossRef] [Green Version]
- Takkar, S.; Sharma, V.; Ghosh, S.; Suri, A.; Sarkar, C.; Kulshreshtha, R. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS. Cell. Oncol. 2021, 44, 433–451. [Google Scholar] [CrossRef]
- Zhu, J.Y.; Huang, X.H.; Fu, Y.L.; Wang, Y.; Zheng, P.; Liu, Y.; Han, Z. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes. Dis. Model. Mech. 2022, 15, dmm048953. [Google Scholar] [CrossRef]
- Kawachi, Y.; Maruyama, H.; Ishitsuka, Y.; Fujisawa, Y.; Furuta, J.; Nakamura, Y.; Ichikawa, E.; Furumura, M.; Otsuka, F. NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells. Exp. Dermatol. 2013, 22, 262–265. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.F.; Hudson, F.Z.; Xu, Z.M.; Tritz, R.; Rojas, M.; Patel, C.; Haigh, S.B.; Bordan, Z.; Ingram, D.A.; Fulton, D.J.; et al. Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. Investig. Ophth. Vis. Sci. 2018, 59, 2520–2528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zbytek, B.; Peacock, D.L.; Seagroves, T.N.; Slominski, A. Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinology 2013, 5, 239–251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bedogni, B.; Welford, S.M.; Cassarino, D.S.; Nickoloff, B.J.; Giaccia, A.J.; Powell, M.B. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005, 8, 443–454. [Google Scholar] [CrossRef] [Green Version]
- Bedogni, B.; Warneke, J.A.; Nickoloff, B.J.; Giaccia, A.J.; Powell, M.B. Notch1 is an effector of Akt and hypoxia in melanoma development. J. Clin. Investig. 2008, 118, 3660–3670. [Google Scholar] [CrossRef] [Green Version]
- Garcia-Borron, J.C.; Sanchez-Laorden, B.L.; Jimenez-Cervantes, C. Melanocortin-1 receptor structure and functional regulation. Pigment. Cell Res. 2005, 18, 393–410. [Google Scholar] [CrossRef]
- Garraway, L.A.; Widlund, H.R.; Rubin, M.A.; Getz, G.; Berger, A.J.; Ramaswamy, S.; Beroukhim, R.; Milner, D.A.; Granter, S.R.; Du, J.Y.; et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436, 117–122. [Google Scholar] [CrossRef]
- Hartman, M.L.; Czyz, M. MITF in melanoma: Mechanisms behind its expression and activity. Cell. Mol. Life Sci. 2015, 72, 1249–1260. [Google Scholar] [CrossRef] [Green Version]
- Busca, R.; Berra, E.; Gaggioli, C.; Khaled, M.; Bille, K.; Marchetti, B.; Thyss, R.; Fitsialos, G.; Larribere, L.; Bertolotto, C.; et al. Hypoxia-inducible factor 1alpha is a new target of mic.crophthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 2005, 170, 49–59. [Google Scholar] [CrossRef] [Green Version]
- Feige, E.; Yokoyama, S.; Levy, C.; Khaled, M.; Igras, V.; Lin, R.J.; Lee, S.; Widlund, H.R.; Granter, S.R.; Kung, A.L.; et al. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc. Natl. Acad. Sci. USA 2011, 108, E924–E933. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kawakami, A.; Fisher, D.E. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab. Investig. 2017, 97, 649–656. [Google Scholar] [CrossRef] [Green Version]
- Wong, C.S.; Strange, R.C.; Lear, J.T. Basal cell carcinoma. BMJ 2003, 327, 794–798. [Google Scholar] [CrossRef] [PubMed]
- Dessinioti, C.; Antoniou, C.; Katsambas, A.; Stratigos, A.J. Basal Cell Carcinoma: What’s New Under the Sun. Photochem. Photobiol. 2010, 86, 481–491. [Google Scholar] [CrossRef] [PubMed]
- Peris, K.; Fargnoli, M.C.; Garbe, C.; Kaufmann, R.; Bastholt, L.; Seguin, N.B.; Bataille, V.; del Marmol, V.; Dummer, R.; Harwood, C.A.; et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur. J. Cancer 2019, 118, 10–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, S. Basal cell carcinoma. Arch. Plast. Surg. 2012, 39, 166–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bitar, G.J.; Herman, C.K.; Dahman, M.I.; Hoard, M.A. Basal cell nevus syndrome: Guidelines for early detection. Am. Fam. Physician 2002, 65, 2501–2504. [Google Scholar] [PubMed]
- Witmanowski, H.; Szychta, P.; Blochowiak, K.; Jundzill, A.; Czajkowski, R. Basal cell nevus syndrome (Gorlin-Goltz syndrome): Genetic predisposition, clinical picture and treatment. Postep. Dermatol. Allergol. 2017, 34, 381–387. [Google Scholar] [CrossRef]
- Di Nardo, L.; Pellegrini, C.; Di Stefani, A.; Ricci, F.; Fossati, B.; Del Regno, L.; Carbone, C.; Piro, G.; Corbo, V.; Delfino, P.; et al. Molecular alterations in basal cell carcinoma subtypes. Sci Rep. 2021, 11, 13206. [Google Scholar] [CrossRef]
- Gailani, M.R.; StahleBackdahl, M.; Leffell, D.J.; Glynn, M.; Zaphiropoulos, P.G.; Pressman, C.; Unden, A.B.; Dean, M.; Brash, D.E.; Bale, A.E.; et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 1996, 14, 78–81. [Google Scholar] [CrossRef]
- Aszterbaum, M.; Rothman, A.; Johnson, R.L.; Fisher, M.; Xie, J.W.; Bonifas, J.M.; Zhang, X.L.; Scott, M.P.; Epstein, E.H. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Investig. Dermatol. 1998, 110, 885–888. [Google Scholar] [CrossRef] [Green Version]
- Atwood, S.X.; Sarin, K.Y.; Whitson, R.J.; Li, J.R.; Kim, G.; Rezaee, M.; Ally, M.S.; Kim, J.; Yao, C.; Chang, A.L.S.; et al. Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma. Cancer Cell 2015, 27, 342–353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sekulic, A.; Von Hoff, D. Hedgehog Pathway Inhibition. Cell 2016, 164, 831. [Google Scholar] [CrossRef] [PubMed]
- Hedgehog Inhibitor Approved for BCC. Cancer Discov. 2015, 5, 1011. [CrossRef] [Green Version]
- Jacobsen, A.A.; Aldahan, A.S.; Hughes, O.B.; Shah, V.V.; Strasswimmer, J. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma A Systematic Review and Pooled Analysis of Interventional Studies. Jama Dermatol. 2016, 152, 816–824. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brinkhuizen, T.; Weijzen, C.A.H.; Eben, J.; Thissen, M.R.; van Marion, A.M.; Lohman, B.G.; Winnepenninckx, V.J.L.; Nelemans, P.J.; van Steensel, M.A.M. Immunohistochemical Analysis of the Mechanistic Target of Rapamycin and Hypoxia Signalling Pathways in Basal Cell Carcinoma and Trichoepithelioma. PLoS ONE 2014, 9, e106427. [Google Scholar] [CrossRef] [Green Version]
- Seleit, I.; Bakry, O.A.; Al-Sharaky, D.R.; Ragab, R.A.A.; Al-Shiemy, S.A. Evaluation of Hypoxia Inducible Factor-1alpha and Glucose Transporter-1 Expression in Non Melanoma Skin Cancer: An Immunohistochemical Study. J. Clin. Diagn. Res. 2017, 11, EC09–EC16. [Google Scholar] [CrossRef]
- Russo, D.; Varricchio, S.; Ilardi, G.; Martino, F.; Di Crescenzo, R.M.; Pignatiello, S.; Scalvenzi, M.; Costa, C.; Mascolo, M.; Merolla, F.; et al. Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma. Front. Oncol. 2021, 11, 659332. [Google Scholar] [CrossRef]
- Bijlsma, M.F.; Groot, A.P.; Oduro, J.P.; Franken, R.J.; Schoenmakers, S.H.H.F.; Peppelenbosch, M.P.; Spek, C.A. Hypoxia induces a hedgehog response mediated by HIF-1 alpha. J. Cell Mol. Med. 2009, 13, 2053–2060. [Google Scholar] [CrossRef] [Green Version]
- Spivak-Kroizman, T.R.; Hostetter, G.; Posner, R.; Aziz, M.; Hu, C.C.; Demeure, M.J.; Von Hoff, D.; Hingorani, S.R.; Palculict, T.B.; Izzo, J.; et al. Hypoxia Triggers Hedgehog-Mediated Tumor-Stromal Interactions in Pancreatic Cancer. Cancer Res. 2013, 73, 3235–3247. [Google Scholar] [CrossRef] [Green Version]
- Onishi, H.; Kai, M.; Odate, S.; Iwasaki, H.; Morifuji, Y.; Ogino, T.; Morisaki, T.; Nakashima, Y.; Katano, M. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci. 2011, 102, 1144–1150. [Google Scholar] [CrossRef]
- Fania, L.; Didona, D.; Di Pietro, F.R.; Verkhovskaia, S.; Morese, R.; Paolino, G.; Donati, M.; Ricci, F.; Coco, V.; Ricci, F.; et al. Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 2021, 9, 171. [Google Scholar] [CrossRef] [PubMed]
- Salasche, S.J. Epidemiology of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 2000, 42, 4–7. [Google Scholar] [CrossRef] [PubMed]
- Biao, T.; Cai-Feng, H.; Xiao-Hong, L.; Xiao-Li, C.; Wen-Bei, L.; Jun, W.; Chao, C.; Tao, Y. From Bowen disease to cutaneous squamous cell carcinoma: Eight markers were verified from transcriptomic and proteomic analyses. J. Transl. Med. 2022, 20, 416. [Google Scholar] [CrossRef]
- Ratushny, V.; Gober, M.D.; Hick, R.; Ridky, T.W.; Seykora, J.T. From keratinocyte to cancer: The pathogenesis and modeling of cutaneous squamous cell carcinoma. J. Clin. Investig. 2012, 122, 464–472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Glogau, R.G. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 2000, 42, 23–24. [Google Scholar] [CrossRef]
- Marks, R.; Rennie, G.; Selwood, T.S. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988, 1, 795–797. [Google Scholar] [CrossRef]
- Kim, J.H.; Bae, H.C.; Kim, J.; Lee, H.; Ryu, W.I.; Son, E.D.; Lee, T.R.; Jeong, S.H.; Son, S.W. HIF-1alpha-mediated BMP6 down-regulation leads to hyperproliferation and abnormal differentiation of keratinocytes in vitro. Exp. Dermatol. 2018, 27, 1287–1293. [Google Scholar] [CrossRef]
- Park, J.Y.; Jung, J.Y.; Kim, H.J.; Bae, I.H.; Kim, D.Y.; Lee, T.R.; Shin, D.W. Hypoxia leads to abnormal epidermal differentiation via HIF-independent pathways. Biochem. Biophys. Res. Commun. 2016, 469, 251–256. [Google Scholar] [CrossRef]
- Koh, R.; Szeverenyi, I.; Lee, B.; Denil, S.; Lim, S.Y.J.; Benny, P.A.; Grasset, N.; Tan, B.K.; Lane, E.B. Oxygen-Mediated Control of the Keratinocyte Proliferation-Differentiation Axis. J. Investig. Dermatol. 2020, 140, 235–238e233. [Google Scholar] [CrossRef] [Green Version]
- Elson, D.A.; Ryan, H.E.; Snow, J.W.; Johnson, R.; Arbeit, J.M. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 2000, 60, 6189–6195. [Google Scholar]
- Mahfouf, W.; Hosseini, M.; Muzotte, E.; Serrano-Sanchez, M.; Dousset, L.; Moisan, F.; Rachidi, W.; Taieb, A.; Rudolf, J.; Rezvani, H.R. Loss of Epidermal HIF-1alpha Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. J. Investig. Dermatol. 2019, 139, 2016–2028.e7. [Google Scholar] [CrossRef] [PubMed]
- Rezvani, H.R.; Mahfouf, W.; Ali, N.; Chemin, C.; Ged, C.; Kim, A.L.; de Verneuil, H.; Taieb, A.; Bickers, D.R.; Mazurier, F. Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucleic Acids Res. 2010, 38, 797–809. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- An, X.; Xu, G.; Yang, L.; Wang, Y.; Li, Y.; McHepange, U.O.; Shen, G.; Tu, Y.; Tao, J. Expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features. J. Dermatol. 2014, 41, 76–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scortegagna, M.; Martin, R.J.; Kladney, R.D.; Neumann, R.G.; Arbeit, J.M. Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. Cancer Res. 2009, 69, 2638–2646. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davis, D.A.; Rinderknecht, A.S.; Zoeteweij, J.P.; Aoki, Y.; Read-Connole, E.L.; Tosato, G.; Blauvelt, A.; Yarchoan, R. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 2001, 97, 3244–3250. [Google Scholar] [CrossRef] [Green Version]
- Mendez-Solis, O.; Bendjennat, M.; Naipauer, J.; Theodoridis, P.R.; Ho, J.J.D.; Verdun, R.E.; Hare, J.M.; Cesarman, E.; Lee, S.; Mesri, E.A. Kaposi’s sarcoma herpesvirus activates the hypoxia response to usurp HIF2alpha-dependent translation initiation for replication and oncogenesis. Cell Rep. 2021, 37, 110144. [Google Scholar] [CrossRef]
- Viollet, C.; Davis, D.A.; Tekeste, S.S.; Reczko, M.; Ziegelbauer, J.M.; Pezzella, F.; Ragoussis, J.; Yarchoan, R. RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. PLoS Pathog. 2017, 13, e1006143. [Google Scholar] [CrossRef] [Green Version]
- Ho, J.J.D.; Wang, M.; Audas, T.E.; Kwon, D.; Carlsson, S.K.; Timpano, S.; Evagelou, S.L.; Brothers, S.; Gonzalgo, M.L.; Krieger, J.R.; et al. Systemic Reprogramming of Translation Efficiencies on Oxygen Stimulus. Cell Rep. 2016, 14, 1293–1300. [Google Scholar] [CrossRef] [Green Version]
- Uniacke, J.; Holterman, C.E.; Lachance, G.; Franovic, A.; Jacob, M.D.; Fabian, M.R.; Payette, J.; Holcik, M.; Pause, A.; Lee, S. An oxygen-regulated switch in the protein synthesis machinery. Nature 2012, 486, 126–129. [Google Scholar] [CrossRef] [Green Version]
- Zwijnenburg, E.M.; Lubeek, S.F.K.; Werner, J.E.M.; Amir, A.L.; Weijs, W.L.J.; Takes, R.P.; Pegge, S.A.H.; van Herpen, C.M.L.; Adema, G.J.; Kaanders, J. Merkel Cell Carcinoma: New Trends. Cancers 2021, 13, 1614. [Google Scholar] [CrossRef]
- Toberer, F.; Haenssle, H.A.; Heinzel-Gutenbrunner, M.; Enk, A.; Hartschuh, W.; Helmbold, P.; Kutzner, H. Metabolic reprogramming and angiogenesis in primary cutaneous Merkel cell carcinoma: Expression of hypoxia-inducible factor-1alpha and its central downstream factors. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 88–94. [Google Scholar] [CrossRef]
- Kukko, H.; Koljonen, V.; Lassus, P.; Tukiainen, E.; Haglund, C.; Bohling, T. Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma. Anticancer Res. 2007, 27, 2587–2589. [Google Scholar] [PubMed]
- Brunner, M.; Thurnher, D.; Pammer, J.; Geleff, S.; Heiduschka, G.; Reinisch, C.M.; Petzelbauer, P.; Erovic, B.M. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod. Pathol. 2008, 21, 876–884. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kervarrec, T.; Gaboriaud, P.; Tallet, A.; Leblond, V.; Arnold, F.; Berthon, P.; Schweinitzer, S.; Larcher, T.; Guyetant, S.; Schrama, D.; et al. VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma. J. Investig. Dermatol. 2019, 139, 736–739. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meaike, J.D.; Dickey, R.M.; Killion, E.; Bartlett, E.L.; Brown, R.H. Facial Skin Cancer Reconstruction. Semin. Plast. Surg. 2016, 30, 108–121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eskiizmir, G.; Baker, S.; Cingi, C. Nonmelanoma skin cancer of the head and neck: Reconstruction. Facial Plast. Surg. Clin. N. Am. 2012, 20, 493–513. [Google Scholar] [CrossRef] [PubMed]
- Rogers-Vizena, C.R.; Lalonde, D.H.; Menick, F.J.; Bentz, M.L. Surgical treatment and reconstruction of nonmelanoma facial skin cancers. Plast. Reconstr. Surg. 2015, 135, 895e–908e. [Google Scholar] [CrossRef]
- Chen, A.; Albertini, J.G.; Bordeaux, J.S.; Chen, M.W.; Cook, J.L.; Davidson, C.; Donnelly, K.C.; Galaria, I.I.; Hannan, C.M.; Kantor, J.; et al. Evidence-based clinical practice guideline: Reconstruction after skin cancer resection. J. Am. Acad. Dermatol. 2021, 85, 423–441. [Google Scholar] [CrossRef]
- Lucas, J.B. The Physiology and Biomechanics of Skin Flaps. Facial Plast. Surg. Clin. N. Am. 2017, 25, 303–311. [Google Scholar] [CrossRef]
- Chang, K.H.; Shoureshi, P.; Lay, F.; Sebastian, R.; Alikhassy Habibabady, Z.; Born, L.J.; Marti, G.P.; Meltzer, S.J.; Abraham, J.M.; Harmon, J.W. Preconditioning of surgical pedicle flaps with DNA plasmid expressing hypoxia-inducible factor-1alpha (HIF-1alpha) promotes tissue viability. Gene Ther. 2021, 28, 319–328. [Google Scholar] [CrossRef]
- Takaku, M.; Tomita, S.; Kurobe, H.; Kihira, Y.; Morimoto, A.; Higashida, M.; Ikeda, Y.; Ushiyama, A.; Hashimoto, I.; Nakanishi, H.; et al. Systemic preconditioning by a prolyl hydroxylase inhibitor promotes prevention of skin flap necrosis via HIF-1-induced bone marrow-derived cells. PLoS ONE 2012, 7, e42964. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalucka, J.; Ettinger, A.; Franke, K.; Mamlouk, S.; Singh, R.P.; Farhat, K.; Muschter, A.; Olbrich, S.; Breier, G.; Katschinski, D.M.; et al. Loss of epithelial hypoxia-inducible factor prolyl hydroxylase 2 accelerates skin wound healing in mice. Mol. Cell. Biol. 2013, 33, 3426–3438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Botusan, I.R.; Sunkari, V.G.; Savu, O.; Catrina, A.I.; Grunler, J.; Lindberg, S.; Pereira, T.; Yla-Herttuala, S.; Poellinger, L.; Brismar, K.; et al. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc. Natl. Acad. Sci. USA 2008, 105, 19426–19431. [Google Scholar] [CrossRef] [Green Version]
- Duscher, D.; Januszyk, M.; Maan, Z.N.; Whittam, A.J.; Hu, M.S.; Walmsley, G.G.; Dong, Y.; Khong, S.M.; Longaker, M.T.; Gurtner, G.C. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast. Reconstr. Surg. 2017, 139, 695e–706e. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duscher, D.; Neofytou, E.; Wong, V.W.; Maan, Z.N.; Rennert, R.C.; Inayathullah, M.; Januszyk, M.; Rodrigues, M.; Malkovskiy, A.V.; Whitmore, A.J.; et al. Transdermal deferoxamine prevents pressure-induced diabetic ulcers. Proc. Natl. Acad. Sci. USA 2015, 112, 94–99. [Google Scholar] [CrossRef] [Green Version]
- Wang, C.; Cai, Y.; Zhang, Y.; Xiong, Z.; Li, G.; Cui, L. Local injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1alpha and VEGF expression. PLoS ONE 2014, 9, e100818. [Google Scholar] [CrossRef]
- Chen, G.J.; Chen, Y.H.; Yang, X.Q.; Li, Z.J. Nano-microcapsule basic fibroblast growth factor combined with hypoxia-inducible factor-1 improves random skin flap survival in rats. Mol. Med. Rep. 2016, 13, 1661–1666. [Google Scholar] [CrossRef] [Green Version]
- Gersch, R.P.; Fourman, M.S.; Phillips, B.T.; Nasser, A.; McClain, S.A.; Khan, S.U.; Dagum, A.B.; Bui, D.T. AdVEGF-All6A+ Preconditioning of Murine Ischemic Skin Flaps Is Comparable to Surgical Delay. Plast. Reconstr. Surg. Glob. Open 2015, 3, e494. [Google Scholar] [CrossRef]
- Liu, Y.; Li, W.; Ma, X.; He, J.; Lin, Y.; Lin, D. Rivastigmine Regulates the HIF-1alpha/VEGF Signaling Pathway to Induce Angiogenesis and Improves the Survival of Random Flaps in Rats. Front. Pharmacol. 2021, 12, 818907. [Google Scholar] [CrossRef]
- Gaete, D.; Rodriguez, D.; Watts, D.; Sormendi, S.; Chavakis, T.; Wielockx, B. HIF-Prolyl Hydroxylase Domain Proteins (PHDs) in Cancer-Potential Targets for Anti-Tumor Therapy? Cancers 2021, 13, 988. [Google Scholar] [CrossRef]
- Wang, L.; Jin, Z.; Wang, J.; Chen, S.; Dai, L.; Lin, D.; Wu, L.; Gao, W. Detrimental effect of Hypoxia-inducible factor-1alpha-induced autophagy on multiterritory perforator flap survival in rats. Sci. Rep. 2017, 7, 11791. [Google Scholar] [CrossRef] [Green Version]
- Kuntscher, M.V.; Hartmann, B.; Germann, G. Remote ischemic preconditioning of flaps: A review. Microsurgery 2005, 25, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Zahir, K.S.; Syed, S.A.; Zink, J.R.; Restifo, R.J.; Thomson, J.G. Ischemic preconditioning improves the survival of skin and myocutaneous flaps in a rat model. Plast. Reconstr. Surg. 1998, 102, 140–150; discussion 151–142. [Google Scholar] [CrossRef] [PubMed]
- Pu, C.M.; Liu, C.W.; Liang, C.J.; Yen, Y.H.; Chen, S.H.; Jiang-Shieh, Y.F.; Chien, C.L.; Chen, Y.C.; Chen, Y.L. Adipose-Derived Stem Cells Protect Skin Flaps against Ischemia/Reperfusion Injury via IL-6 Expression. J. Investig. Dermatol. 2017, 137, 1353–1362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reichenberger, M.A.; Heimer, S.; Schaefer, A.; Lass, U.; Gebhard, M.M.; Germann, G.; Leimer, U.; Kollensperger, E.; Mueller, W. Adipose derived stem cells protect skin flaps against ischemia-reperfusion injury. Stem. Cell Rev. Rep. 2012, 8, 854–862. [Google Scholar] [CrossRef] [PubMed]
- Uysal, A.C.; Mizuno, H.; Tobita, M.; Ogawa, R.; Hyakusoku, H. The effect of adipose-derived stem cells on ischemia-reperfusion injury: Immunohistochemical and ultrastructural evaluation. Plast. Reconstr. Surg. 2009, 124, 804–815. [Google Scholar] [CrossRef]
- Xie, L.; Wang, J.; Zhang, Y.; Chen, H.; Lin, D.; Ding, J.; Xuan, J.; Chen, Q.; Cai, L. The effects of local injection of exosomes derived from BMSCs on random skin flap in rats. Am. J. Transl. Res. 2019, 11, 7063–7073. [Google Scholar]
- Guo, L.; Chen, Y.; Feng, X.; Sun, D.; Sun, J.; Mou, S.; Zhao, K.; An, R. Oxidative stress-induced endothelial cells-derived exosomes accelerate skin flap survival through Lnc NEAT1-mediated promotion of endothelial progenitor cell function. Stem. Cell Res. Ther. 2022, 13, 325. [Google Scholar] [CrossRef]
- Niu, Q.; Yang, Y.; Li, D.; Guo, W.; Wang, C.; Xu, H.; Feng, Z.; Han, Z. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells Alleviate Ischemia-Reperfusion Injury and Promote Survival of Skin Flaps in Rats. Life 2022, 12, 1567. [Google Scholar] [CrossRef]
- Bai, Y.; Han, Y.D.; Yan, X.L.; Ren, J.; Zeng, Q.; Li, X.D.; Pei, X.T.; Han, Y. Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 2018, 500, 310–317. [Google Scholar] [CrossRef]
- Yue, Y.; Zhang, P.; Liu, D.; Yang, J.F.; Nie, C.; Yang, D. Hypoxia preconditioning enhances the viability of ADSCs to increase the survival rate of ischemic skin flaps in rats. Aesthetic Plast. Surg. 2013, 37, 159–170. [Google Scholar] [CrossRef]
- Garcia, J.; Hurwitz, H.I.; Sandler, A.B.; Miles, D.; Coleman, R.L.; Deurloo, R.; Chinot, O.L. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 2020, 86, 102017. [Google Scholar] [CrossRef]
- Fallah, J.; Rini, B.I. HIF Inhibitors: Status of Current Clinical Development. Curr. Oncol. Rep. 2019, 21, 6. [Google Scholar] [CrossRef] [PubMed]
- Fallah, J.; Brave, M.H.; Weinstock, C.; Mehta, G.U.; Bradford, D.; Gittleman, H.; Bloomquist, E.W.; Charlab, R.; Hamed, S.S.; Miller, C.P.; et al. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors. Clin. Cancer Res. 2022, 28, 4843–4848. [Google Scholar] [CrossRef] [PubMed]
- Gupta, N.; Wish, J.B. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am. J. Kidney Dis. 2017, 69, 815–826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shao, Y.L.; Liu, B.; Di, Z.H.; Zhang, G.; Sun, L.D.; Li, L.L.; Yan, C.H. Engineering of Upconverted Metal-Organic Frameworks for Near-Infrared Light-Triggered Combinational Photodynamic/Chemo-/Immunotherapy against Hypoxic Tumors. J. Am. Chem. Soc. 2020, 142, 3939–3946. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Zhou, Z.G.; Hou, J.T.; Xiong, W.; Kim, H.; Chen, J.S.; Zheng, C.J.; Jiang, X.; Yoon, J.; Shen, J.L. Tumor Selective Metabolic Reprogramming as a Prospective PD-L1 Depression Strategy to Reactivate Immunotherapy. Adv. Mater. 2022, 34, 2206121. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.G.; Chen, J.S.; Liu, Y.; Zheng, C.J.; Luo, W.J.; Chen, L.L.; Zhou, S.; Li, Z.M.; Shen, J.L. Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy. Acta Pharm. Sin. B 2022, 12, 4204–4223. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.; Liu, Y.; Song, W.; Jiang, X.; Deng, Z.; Xiong, W.; Shen, J. Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy. J. Control. Release 2022, 352, 793–812. [Google Scholar] [CrossRef] [PubMed]
- Qiao, Y.; Yang, F.; Xie, T.; Du, Z.; Zhong, D.; Qi, Y.; Li, Y.; Li, W.; Lu, Z.; Rao, J.; et al. Engineered algae: A novel oxygen-generating system for effective treatment of hypoxic cancer. Sci. Adv. 2020, 6, eaba5996. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.G.; Cheng, Y.H.; Yu, P.; Wang, H.R.; Zhang, Y.; Xu, H.H.; Ye, Q.S.; Yuan, A.H.; Hu, Y.Q.; Wu, J.H. Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy. Nat. Commun. 2019, 10, 1580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jeon, S.; Jeon, M.; Choi, S.; Yoo, S.; Park, S.; Lee, M.; Kim, I. Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications. Int. J. Mol. Sci. 2023, 24, 4430. https://doi.org/10.3390/ijms24054430
Jeon S, Jeon M, Choi S, Yoo S, Park S, Lee M, Kim I. Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications. International Journal of Molecular Sciences. 2023; 24(5):4430. https://doi.org/10.3390/ijms24054430
Chicago/Turabian StyleJeon, Sungmi, Miyeon Jeon, Sanga Choi, Seongkyeong Yoo, Soohyun Park, Mingyu Lee, and Iljin Kim. 2023. "Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications" International Journal of Molecular Sciences 24, no. 5: 4430. https://doi.org/10.3390/ijms24054430